Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say

Bausch (BHC) reported Q2 2025 revenue of $2.53 billion, a 5.3% year-over-year increase that surpassed consensus estimates by 2.42%, primarily driven by strong performances in Salix (+12.4%) and Solta Medical (+25.5%). However, diluted EPS of $0.90 missed the $0.97 consensus by 7.22%, despite total Bausch + Lomb and Bausch Health (excl. B+L) revenues both exceeding analyst expectations. While the stock has recently lagged the broader S&P 500, its current Zacks Rank #2 (Buy) suggests potential for near-term outperformance.

Analysis

Bausch Health's Q2 2025 results present a mixed financial picture, characterized by a revenue beat but a notable earnings miss. The company reported total revenue of $2.53 billion, representing a 5.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 2.42%. This top-line strength was not uniform, being primarily driven by significant growth in the Salix segment, which grew 12.4% YoY to $627 million, and the Solta Medical segment, which expanded by an impressive 25.5% YoY to $128 million. Both of these key segments exceeded analyst expectations. However, this growth was contrasted by persistent weakness in the Diversified Products division, which saw revenues decline 12.8% YoY, led by a sharp 25.7% contraction in Ortho Dermatology. Despite the overall revenue outperformance, earnings per share came in at $0.90, missing the consensus estimate of $0.97 by 7.22% and showing minimal growth from the prior-year quarter. The stock's recent performance of a 0.4% gain has significantly lagged the S&P 500 composite's 3.4% increase, reflecting investor concern over profitability and the drag from underperforming segments.

Key Decisions for Investors

• Investors should weigh the positive top-line momentum, driven by the strong performance in the Salix and Solta Medical segments, against the persistent pressure on profitability indicated by the 7.22% EPS miss.
• It is critical to monitor the performance of the high-growth Salix and Solta segments, as their continued outperformance is essential to offset the significant, ongoing declines in the Diversified Products division.
• Given the stock's recent underperformance relative to the broader market, the Zacks Rank #2 (Buy) suggests a potential value opportunity, but this is contingent on the company's ability to improve margins and stabilize the contracting business units.